Norcantharidin enhances ABT-737-induced apoptosis in hepatocellular carcinoma cells by transcriptional repression of Mcl-1

Cellular Signalling

Volumn 24, Issue 9, 2012, Pages 1803-1809

  Zhang, Shuijun ^a   Li, Gongquan ^a   Ma, Xiuxian ^a   Wang, Yu ^b   Liu, Guangzhi ^b   Feng, Liushun ^a   Zhao, Yongfu ^a   Zhang, Gong ^a   Wu, Yang ^a   Ye, Xuexiang ^a   Qin, Baoming ^a   Lu, Jianfeng ^a,c  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b HENAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

^c UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

ABT 737; Apoptosis; Hepatocelluar carcinoma cells; Norcantharidin

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; CASPASE 3; CASPASE 9; CYTOCHROME C; NORCANTHARIDIN; PROTEIN BAK; PROTEIN BAX; PROTEIN MCL 1;

APOPTOSIS; ARTICLE; BEETLE; BLISTER BEETLE; CANCER CELL CULTURE; CARCINOMA CELL; CELL VIABILITY; CHINESE MEDICINE; CONTROLLED STUDY; DRUG EFFICACY; DRUG STRUCTURE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MEMBRANE PERMEABILITY; MITOCHONDRIAL MEMBRANE; MITOCHONDRION; MYLABRIS; OUTER MEMBRANE; PRIORITY JOURNAL; PROTEIN SECRETION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BICYCLO COMPOUNDS, HETEROCYCLIC; BIPHENYL COMPOUNDS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LIVER NEOPLASMS; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; NITROPHENOLS; PIPERAZINES; SULFONAMIDES; TRANSCRIPTION, GENETIC;

EID: 84862638645     PISSN: 08986568     EISSN: 18733913     Source Type: Journal    
DOI: 10.1016/j.cellsig.2012.05.009     Document Type: Article

References (40)

1. Burroughs A., Hochhauser D., Meyer T. The Lancet Oncology 2004, 5:409-418.
2. Marrero J., Kudo M., Bronowicki J. The Oncologist 2010, 15(Suppl. 4):23-33.
3. Jiang X., Wang X. Annual Review of Biochemistry 2004, 73:87-106.
4. Ren D., Tu H.C., Kim H., Wang G.X., Bean G.R., Takeuchi O., et al. Science 2010, 330:1390-1393.
5. Takehara T., Liu X., Fujimoto J., Friedman S.L., Takahashi H. Hepatology 2001, 34:55-61.
6. Sieghart W., Losert D., Strommer S., Cejka D., Schmid K., Rasoul-Rockenschaub S., et al. Journal of Hepatology 2006, 44:151-157.
7. Cragg M.S., Harris C., Strasser A., Scott C.L. Nature Reviews. Cancer 2009, 9:321-326.
8. Khaw S.L., Huang D.C., Roberts A.W. Pathology 2011, 43:525-535.
9. Oltersdorf T., Elmore S.W., Shoemaker A.R., Armstrong R.C., Augeri D.J., Belli B.A., et al. Nature 2005, 435:677-681.
10. Konopleva M., Contractor R., Tsao T., Samudio I., Ruvolo P.P., Kitada S., et al. Cancer Cell 2006, 10:375-388.
11. van Delft M.F., Wei A.H., Mason K.D., Vandenberg C.J., Chen L., Czabotar P.E., et al. Cancer Cell 2006, 10:389-399.
12. Chen S., Dai Y., Harada H., Dent P., Grant S. Cancer Research 2007, 67:782-791.
13. Miller L.A., Goldstein N.B., Johannes W.U., Walton C.H., Fujita M., Norris D.A., et al. The Journal of Investigative Dermatology 2009, 129:964-971.
14. Lin X., Morgan-Lappe S., Huang X., Li L., Zakula D.M., Vernetti L.A., et al. Oncogene 2007, 26:3972-3979.
15. Hikita H., Takehara T., Shimizu S., Kodama T., Shigekawa M., Iwase K., et al. Hepatology 2010, 52:1310-1321.
16. Tromp J.M., Geest C.R., Breij E.C., Elias J.A., van Laar J., Luijks D.M., et al. Clinical Cancer Research 2012, 18:487-498.
17. Konopleva M., Milella M., Ruvolo P., Watts J.C., Ricciardi M.R., Korchin B., et al. Leukemia 2011, 26:778-787.
18. Song J.H., Kraft A.S. Cancer Research 2012, 72:294-303.
19. Xu H., Krystal G.W. Clinical Cancer Research 2010, 16:4392-4400.
20. Olberding K.E., Wang X., Zhu Y., Pan J., Rai S.N., Li C. Cancer Biology & Therapy 2010, 10:918-929.
21. Wang G. International Journal of Cancer 2002, 100:158-165.
22. Yang P.Y., Chen M.F., Kao Y.H., Hu D.N., Chang F.R., Wu Y.C. Toxicology In Vitro 2011, 25:699-707.
23. Huang Y., Liu Q., Liu K., Yagasaki K., Zhang G. Cytotechnology 2009, 59:201-208.
24. Li G.Q., Zhang S.J., Lü J.F., Wu Y., Li J., Zhang G., et al. Zhonghua Yi Xue Za Zhi 2010, 90:2145-2148.
25. Ding W., Ni H., Chen X., Yu J., Zhang L., Yin X. Molecular Cancer Therapeutics 2007, 6:1062-1069.
26. Wei M.C., Zong W.X., Cheng E.H., Lindsten T., Panoutsakopoulou V., Ross A.J., et al. Science 2001, 292:727-730.
27. Yang E.B., Tang W.Y., Zhang K., Cheng L.Y., Mack P.O. Cancer Letters 1997, 117:93-98.
28. Liu F.Y., Li Y., Peng Y.M., Ye K., Li J., Liu Y.H., et al. American Journal of Nephrology 2008, 28:465-477.
29. Wang G.S. Journal of Ethnopharmacology 1989, 26:147-162.
30. Liu X.H., Blazsek I., Comisso M., Legras S., Marion S., Quittet P., et al. European Journal of Cancer 1995, 31:953-963.
31. Chen Y.J., Kuo C.D., Tsai Y.M., Yu C.C., Wang G.S., Liao H.F. Anti-Cancer Drugs 2008, 19:55-64.
32. Li J.L., Cai Y.C., Liu X.H., Xian L.J. Anti-Cancer Drugs 2006, 17:307-314.
33. Yang H., Guo W., Xu B., Li M., Cui J. Anti-Cancer Drugs 2007, 18:1133-1137.
34. Chang C., Zhu Y., Mei J., Liu S., Luo J. Journal of Experimental & Clinical Cancer Research 2010, 29:145.
35. Gojo I., Zhang B., Fenton R.G. Clinical Cancer Research 2002, 8:3527-3538.
36. Chen Y.J., Chang W.M., Liu Y.W., Lee C.Y., Jang Y.H., Kuo C.D., Liao H.F. Chemico-Biological Interactions 2009, 181:440-446.
37. Wittmann S., Bali P., Donapaty S., Nimmanapalli R., Guo F., Yamaguchi H., et al. Cancer Research 2003, 63:93-99.
38. Chen Y.C., Chang S.C., Wu M.H., Chuang K.A., Wu J.Y., Tsai W.J., et al. Life Sciences 2009, 84:218-226.
39. Zheng L., Yang W., Zhang C., Ding W., Zhu H., Lin N., et al. Cancer Letters 2011, 309:27-36.
40. Dash R., Azab B., Quinn B.A., Shen X., Wang X., Das S.K., et al. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:8785-8790.